Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494111 · ClinicalTrials.gov registry record · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
A Phase 2 study of Lymphedema and Fibrosis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
- 1
- Study location
NCT06494111 is a Phase 2 study of Lymphedema and Fibrosis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 295 participants, below the 9,291-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06494111, a Phase 2 study of Lymphedema and Fibrosis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.
Conditions Studied
Interventions
- DRUG Pentoxifylline
- DRUG Pravastatin
- DRUG Tocopherol
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2031-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494111
The ClinicalTrials.gov registry entry for NCT06494111 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,291-participant average among 34 other Lymphedema trials with a reported enrollment target (97% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphedema appearing as the primary indexed condition, and to 3 interventions - of which Pentoxifylline is the first listed.
NCT06494111 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06494111 about?
NCT06494111 is a clinical study titled "Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)". To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.
What is the current status of trial NCT06494111?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2025-02-13. Estimated completion is 2031-03-01.
What conditions does trial NCT06494111 study?
This clinical trial studies the following conditions: Lymphedema, Fibrosis.
What interventions are being tested in trial NCT06494111?
The interventions under investigation include: Pentoxifylline (DRUG), Pravastatin (DRUG), Tocopherol (DRUG).
Who is sponsoring clinical trial NCT06494111?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494111 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
COMPLETED · Phase 2
-
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
COMPLETED · Phase 2
-
Pycnogenol for the Treatment of Lymphedema
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.